Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1

NCT ID: NCT02054299

Last Updated: 2016-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-30
• Study Completion Date: 2016-02-29

Brief Summary

The purpose of this study is to determine the effect of the organic cation transporter OCT1 polymorphisms on the pharmacokinetics of several drugs in order to explain efficacy and adverse effects.

Conditions

Drug Metabolism; Membrane Transport

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Drug application

6 treatment periods. On each period one of the following interventions

Group Type: EXPERIMENTAL

Drug application Amitriptyline

Intervention Type: DRUG

Amitriptyline: 25 mg, single oral application

Drug application Desvenlafaxine

Intervention Type: DRUG

Desvenlafaxine: 50 mg, single oral application

Drug application Sumatriptan

Intervention Type: DRUG

Sumatriptan: 50 mg, single oral application

Drug application Proguanil

Intervention Type: DRUG

Proguanil: 200mg, single oral application

Drug application Fenoterol

Intervention Type: DRUG

Fenoterol: 180 mcg, single intravenous application

Drug application Thiamine

Intervention Type: DRUG

Thiamine: 200mg, single oral application

Interventions

Drug application Amitriptyline

Amitriptyline: 25 mg, single oral application

Intervention Type: DRUG

Drug application Desvenlafaxine

Desvenlafaxine: 50 mg, single oral application

Intervention Type: DRUG

Drug application Sumatriptan

Sumatriptan: 50 mg, single oral application

Intervention Type: DRUG

Drug application Proguanil

Proguanil: 200mg, single oral application

Intervention Type: DRUG

Drug application Fenoterol

Fenoterol: 180 mcg, single intravenous application

Intervention Type: DRUG

Drug application Thiamine

Thiamine: 200mg, single oral application

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written informed consent obtained prior to study entry including informed consent for molecular genetic analysis concerning candidate genes relevant for pharmacokinetics and pharmacodynamics of the study medication.

2. Both genders (male and female), as far as feasible, in each of the 3 OCT1 genotype groups, an equal proportion of males and females will be included.

3. Healthy adults aged ≥18 to < 50 years

4. Body weight not less than 48 kg and body mass index (BMI) not less than 17 kg/m² and not greater than 32 kg/m².

5. Willingness to meet the study instructions and to co-operate with the study personal

6. No clinically relevant pathological findings in any of the investigations at the screening visit. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance

7. Systolic blood pressure ≤ 140 mmHg and ≥ 100 mmHg, diastolic blood pressure ≤ 90 mmHg and ≥ 60 mmHg and heart rate ≤ 90 bpm and ≥ 50 bpm at screening visit

8. Female subjects will only be included if they express their willingness not to become pregnant during the entire study period by practicing abstinence or reliable methods of contraception as specified in the respective protocol section.

Exclusion Criteria

1. Unwillingness or inability to give informed consent

2. Involvement in the planning and conduct of the study (applies to staff directly employed at the study site / department)

3. Participation in a clinical study or use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the first dose of study drugs.

4. Blood, plasma or thrombocyte donation during the last 15 days prior to application of the test drugs.

5. Any planned surgical treatment during the last 14 days prior and 14 days after the application of the test drugs.

6. Known pregnancy or lactation period

7. Any relevant pathological findings in any of the investigations at the screening visit including significant abnormalities as result of the medical-screening-laboratory-analysis, especially of the liver and kidney related parameters unless judged as medically irrelevant.

8. QTcF > 450 ms in screening ECG

9. Systolic blood pressure > 140 mmHg and < 100 mmHg, diastolic blood pressure > 90 mmHg and < 60 mmHg and heart rate > 90 bpm and < 50 bpm pre-dose at treatment period 4 (Amitriptyline)

10. Any disease affecting liver or kidney or impairment of the liver or kidney-function

11. Any cardiovascular disease

12. Moderate to severe hypertension requiring medication therapy

13. Bronchogenic asthma requiring constant drug treatment (stages 2 to 4 asthma)

14. Diabetes mellitus, hyperthyroidism, hypothyroidism

15. Glaucoma

16. Symptomatic prostatic hyperplasia

17. Any medical constellation that increases risk of bleeding, including chronic treatment with NSAID or COX-2 inhibitors

18. History of alcohol and/or drug abuse and/or any abusive use of medicaments and/or positive drug screen

19. History of any psychiatric or neurologic disorder. If there are any doubts at the screening visit on whether a person is suffering from a depression or not he or she will be excluded from the study or examined by a psychiatrist for clarification before inclusion.

20. Any major gastrointestinal disease and any gastrointestinal disorder that is expected to significantly interfere with the pharmacokinetics of the study drug

21. Gastrointestinal surgery which may interfere with the pharmacokinetics of the study drug (except appendectomy or herniotomy)

22. Taking any medication within 7 days before or during the trial with the following exceptions: Oral contraceptive drug used will be documented but will not be an exclusion criterion. Other medication might be allowed on single case basis if considered necessary for the subject's safety and well-being and if interactions with the study medication are judged as irrelevant.

23. Any other findings that could compromise the safety of the participant or the quality of the study-results

24. Any known hypersensitivity or allergic reactions to any of the tested drugs

25. History of severe hypersensitivity reactions and anaphylaxis

26. Any other clinically significant diseases as judged by the investigator

27. Body temperature > 37.5°C prior to drug application

28. Known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no laboratory diagnostics concerning these diseases will be performed within the present study)

29. Inability or unwillingness to avoid any intake of alcohol from 48 h prior to until 72 hours after Investigational Medicinal Product (IMP) application application

30. Pregnancy (positive pregnancy test performed prior to drug administration)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Medical Center Goettingen

OTHER

Sponsor Role: lead

Responsible Party

Johannes Matthaei

Sub-investigator, Principal investigator is Prof. Juergen Brockmoeller

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Juergen Brockmoeller, Prof.

Role: STUDY_DIRECTOR

University Medical Center Goettingen

Locations

Department of Clinical Pharmacology, University Medical Center Goettingen

Göttingen, , Germany

Countries

Germany

References

Tzvetkov MV, Matthaei J, Pojar S, Faltraco F, Vogler S, Prukop T, Seitz T, Brockmoller J. Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency. Clin Pharmacol Ther. 2018 May;103(5):868-878. doi: 10.1002/cpt.812. Epub 2017 Dec 8.

Reference Type: DERIVED

PMID: 28791698 (View on PubMed)

Other Identifiers

2012-003546-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PG-OCT

Identifier Type: -

Identifier Source: org_study_id